Potential pharmacotherapy of Alzheimer disease. A comparison of various forms of physostigmine administration.
This paper reviews clinical trials with physostigmine administered to Alzheimer patients using three different routes of administration: oral, i.v. and intracerebroventricular (i.c.v.). It compares results obtained with three different routes by the authors as well as by other authors. Particular emphasis is given to a novel type of physostigmine administration, the i.c.v. route. Advantages and disadvantages, as well as side effects of each route are presented and discussed.
D000284:Administration, Oral; D000544:Alzheimer Disease / Q000097:blood / Q000188:drug therapy*; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002091:Butyrylcholinesterase / Q000097:blood; D002799:Cholinergic Fibers / Q000187:drug effects / Q000378:metabolism*; D002802:Cholinesterases / Q000097:blood; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D007275:Injections, Intravenous; D007276:Injections, Intraventricular; D008568:Memory / Q000187:drug effects; D010830:Physostigmine / Q000008:administration & dosage / Q000627:therapeutic use*
D010830:Physostigmine; D002091:Butyrylcholinesterase; D002802:Cholinesterases